✦ LIBER ✦

6080 Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI

✍ Scribed by Vasile, E.; Masi, G.; Loupakis, F.; Cupini, S.; Baldi, G.G.; Salvatore, L.; Fornaro, L.; Pfanner, E.; Ricci, S.; Falcone, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6082 Second-line treatments in patients

✍ Masi, G.; Vasile, E.; Loupakis, F.; Fornaro, L.; Salvatore, L.; Cupini, S.; Stas 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

FOLFOXIRI plus bevacizumab as first-line

✍ Loupakis, F.; Cremolini, C.; Salvatore, L.; Masi, G.; Sensi, E.; Schirripa, M.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 651 KB

262 First line simplified FOLFOXIRI in m

✍ G. Masi; G. Allegrini; S. Cupini; L. Marcucci; E. Cerri; I. Brunetti; S. Ricci; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Pharmacodynamic and pharmacogenetic angi

✍ Loupakis, F; Cremolini, C; Fioravanti, A; Orlandi, P; Salvatore, L; Masi, G; Di 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 366 KB

A systematic review of FOLFOXIRI chemoth

✍ F. Montagnani; A. Chiriatti; G. Turrisi; G. Francini; G. Fiorentini 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Dose escalating study of cetuximab and 5

✍ Gunnar Folprecht,Susanne Hamann,Katharina Schütte,Tanja Trarbach… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 460 KB